Understanding Global Roles and Responsibilities of Ethics Committees in Clinical Trials

Introduction: Ethical Oversight in Clinical Research

Ethics Committees—commonly referred to as Institutional Review Boards (IRBs) in the US or Independent Ethics Committees (IECs) elsewhere—are essential for safeguarding the rights, safety, and well-being of human participants in clinical research. With the globalization of trials, these committees play a critical role in ensuring ethical compliance across diverse regulatory environments.

The responsibilities of Ethics Committees (ECs) are rooted in global standards such as the Declaration of Helsinki, ICH-GCP E6(R2), and country-specific guidelines. Regardless of regional differences, their core mandate remains consistent: to uphold bioethical principles and protect human subjects involved in trials.

Composition and Independence of Ethics Committees

According to ICH-GCP, an EC should comprise members with varied backgrounds to ensure a balanced and competent review. A typical committee includes:

• At least one medical scientist
• One legal expert or lawyer
• One social scientist or layperson
• One ethicist or theologian (optional but encouraged)
• Chairperson not affiliated with the trial site

Independence is crucial. Committee members must be free from conflicts of interest with the trial sponsor, CRO, or investigator. In many jurisdictions, ethics committees are institutionally based, while others—like in India’s CDSCO framework—require registration with a central authority to operate.

Primary Responsibilities of Ethics Committees

Ethics Committees have several key responsibilities throughout the clinical trial lifecycle:

• Initial Protocol Review: Assess trial design, risk-benefit ratio, objectives, and inclusion/exclusion criteria.
• Informed Consent Review: Ensure that the consent forms are comprehensive, understandable, and ethically acceptable.
• Ongoing Safety Monitoring: Evaluate serious adverse events (SAEs) and periodic safety reports.
• Review of Amendments: Examine protocol amendments, re-consent needs, and impact on risk assessment.
• Final Study Report Review: Evaluate final outcomes and compliance with ethical principles.

For example, during a Phase III oncology trial, the ethics committee might request a detailed review of patient withdrawal criteria to ensure fairness and safety, especially for vulnerable populations.

Key Global Regulations Governing Ethics Committees

While the responsibilities of ECs are broadly consistent, regional regulations define specific obligations. A few examples include:

To ensure international harmonization, the WHO and CIOMS (Council for International Organizations of Medical Sciences) also provide ethical guidelines that many committees follow in addition to local requirements.

Informed Consent Oversight: A Critical Role

Ethics Committees play a pivotal role in reviewing and approving the informed consent process. They evaluate:

• Language clarity and readability (e.g., 8th-grade reading level)
• Disclosure of trial purpose, risks, and benefits
• Right to withdraw without penalty
• Data confidentiality and privacy safeguards

In multi-country studies, ECs must ensure that local cultural norms are respected in the consent process. For example, some African countries require community consent in addition to individual consent in cluster trials. You can also explore UK’s NIHR guidance on consent form best practices for more insights.

Safety Monitoring and SAE Review

Post-approval, ECs are responsible for ensuring the ongoing safety of trial subjects. Sponsors must notify ECs of:

• SAEs (within timelines—usually 7 to 15 days)
• Suspected Unexpected Serious Adverse Reactions (SUSARs)
• DSMB (Data Safety Monitoring Board) recommendations
• Annual safety reports and periodic updates

The EC may choose to suspend or withdraw trial approval if safety is compromised. This regulatory check helps maintain ethical compliance even after initial approval.

EC SOPs and Record Keeping

All Ethics Committees must maintain detailed Standard Operating Procedures (SOPs) that cover:

• Membership criteria and conflict of interest policy
• Meeting quorum and voting procedures
• Document review workflows and timelines
• Communication with investigators and sponsors

ECs are also required to maintain documentation for at least 3–5 years post-trial depending on regional laws. These records are often reviewed during regulatory inspections and audits by agencies such as FDA or EMA.

Global Harmonization Challenges

Despite common principles, global trials face several harmonization issues when multiple ethics committees are involved:

• Conflicting decisions: One EC may approve a protocol that another EC rejects.
• Diverse documentation standards: Translation and local customization delays approvals.
• Duplicate reviews: Multicenter trials often require several EC reviews for the same protocol.

To address these challenges, some countries (like the UK via HRA) have implemented centralized EC reviews. The EU Clinical Trials Regulation (CTR) also facilitates single ethics reviews across member states.

Conclusion: Ethics Committees as Gatekeepers of Participant Safety

Ethics Committees serve as the moral and regulatory gatekeepers of clinical trials. Their scope—from protocol approval to informed consent review and safety monitoring—ensures that research upholds the dignity, rights, and welfare of participants worldwide.

With rising scrutiny over ethical practices, ECs must continually update their SOPs, training, and review methodologies to remain compliant with global expectations. As research becomes more globalized and complex, their role is more critical than ever in protecting human subjects and maintaining public trust in clinical science.